Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04001647 · ClinicalTrials.gov registry record · Early Phase 1
Targeting ER Stress in Vascular Dysfunction
A Early Phase 1 study, sponsored by Colorado State University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT04001647 is a Early Phase 1 study that was terminated before completion, run by Colorado State University. The registered enrollment target is 17 participants.
The verdict
NCT04001647, a Early Phase 1 study, was terminated before completion, sponsored by Colorado State University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Aging and obesity are both risk factors for cardiovascular disease (CVD). One process that links both of these conditions to CVD is vascular dysfunction. Data from animal studies indicate that endoplasmic reticulum (ER) stress may play an important role in the development of endothelial dysfunction in aging and obesity. Therefore, the goal of this study is to investigate the relative contributions of aging and obesity on vascular dysfunction and ER stress. Additionally, this study will determine if taking an oral supplement for 8 weeks will improve vascular dysfunction and ER stress. Results from this study have the potential to identify a safe treatment option for improving vascular function in aging and obese populations.
Interventions
- DRUG Acetylcholine
- DRUG Sodium Nitroprusside
- DRUG Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2022-08-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04001647
The ClinicalTrials.gov registry entry for NCT04001647 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Colorado State University, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Acetylcholine is the first listed.
NCT04001647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04001647 about?
NCT04001647 is a clinical study titled "Targeting ER Stress in Vascular Dysfunction". Aging and obesity are both risk factors for cardiovascular disease (CVD). One process that links both of these conditions to CVD is vascular dysfunction. Data from animal studies indicate that endoplasmic reticulum (ER) stress may play an important role in the development of endothelial dysfunction ...
What is the current status of trial NCT04001647?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2019-06-01. Estimated completion is 2022-08-16.
What interventions are being tested in trial NCT04001647?
The interventions under investigation include: Acetylcholine (DRUG), Sodium Nitroprusside (DRUG), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT04001647?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.